Pfizer

The NIH starts spending $1.5 billion in new Brain Research through Advancing Innovative Neuro-technologies (BRAIN) projects

by

___

NIH Starts to Spend $4.8 Bil­lion in “Extra” Cures Drug Research Mon­ey (P&T Community):

“The Nation­al Insti­tutes of Health (NIH) launched 110 new brain research projects in the fis­cal year end­ing last Sep­tem­ber (2017) with the first por­tion of the $1.5 bil­lion over 10 years it will hope­ful­ly receive from the 21st Cen­tu­ry Cures Act, which spread a total of $4.8 bil­lion over four NIH pro­grams. That is mon­ey over and above the NIH annu­al appro­pri­a­tion from Con­gress. The oth­er three “Inno­va­tion Funds” are: Pre­ci­sion Med­i­cine, Can­cer Moon­shot, and Regen­er­a­tive Medicine.

The $1.5 bil­lion in new Brain Research through Advanc­ing Inno­v­a­tive Neu­ro-tech­nolo­gies (BRAIN) research mon­ey seems par­tic­u­lar­ly impor­tant giv­en the announce­ment in Jan­u­ary that Pfiz­er was end­ing its Alzheimer’s research pro­gram [Read more…] about The NIH starts spend­ing $1.5 bil­lion in new Brain Research through Advanc­ing Inno­v­a­tive Neu­ro-tech­nolo­gies (BRAIN) projects

With pharma exiting Alzheimer’s research, new hope (and urgency) seen in the combination of brain training and transcranial direct current stimulation (tDCS)

by

___

What does the future hold for the war on Alzheimer’s? (The Globe and Mail):

“After spend­ing huge sums on clin­i­cal trails in recent years, the phar­ma­ceu­ti­cal indus­try has failed to find a drug that can halt the mind-rob­bing dis­ease. And this month, Pfiz­er announced it is end­ing its Alzheimer’s research, although oth­er com­pa­nies haven’t thrown in the tow­el yet. But oth­er pre­ven­tion mea­sures are being explored.

Sev­er­al Toron­to hos­pi­tals are involved in an ambi­tious $10-mil­lion, five-year study to deter­mine whether a com­bi­na­tion of cog­ni­tive reme­di­a­tion – men­tal exer­cis­es – plus elec­tri­cal stim­u­la­tion of the brain can delay [Read more…] about With phar­ma exit­ing Alzheimer’s research, new hope (and urgency) seen in the com­bi­na­tion of brain train­ing and tran­scra­nial direct cur­rent stim­u­la­tion (tDCS)

Akili raises an additional $11.9M; brings Amgen, Merck, Pfizer and Shire to the digital medicine table

by

akili-game—–

Akili Adds Amgen Ven­tures and M Ven­tures* to Series B Financ­ing, Increas­ing Round to $42.4 Mil­lion (press release):

“Akili Inter­ac­tive Labs, Inc. (“Akili”), a dig­i­tal med­i­cine com­pa­ny devel­op­ing nov­el, non-phar­ma­co­log­i­cal ther­a­peu­tics and diag­nos­tics for cog­ni­tive dis­or­ders, today announced an $11.9 mil­lion expan­sion of its recent Series B financ­ing. [Read more…] about Akili rais­es an addi­tion­al $11.9M; brings Amgen, Mer­ck, Pfiz­er and Shire to the dig­i­tal med­i­cine table

Harnessing brain training games to better research, prevent and treat Alzheimer’s Disease

by

HRAkili

—

Brain Train­ing Data­base: Trea­sure Trove for Pre­clin­i­cal Alzheimer’s Research? (Alz­fo­rum):

“Some researchers think brain games in general—which adapt to each user’s cog­ni­tive ability—may one day serve as cog­ni­tive diag­nos­tics to [Read more…] about Har­ness­ing brain train­ing games to bet­ter research, pre­vent and treat Alzheimer’s Disease

Brain Training and Cognitive Assessment Market Surpassed $1.3 Billion In 2013

by

Heads-up: We just announced a new intel­li­gence pack­age aimed at edu­ca­tion, health, gam­ing and tech­nol­o­gy exec­u­tives and innovators.

“Many mar­ket reports pro­vide lit­tle val­ue for the mon­ey. This mar­ket report by Sharp­Brains is the pre­cise oppo­site. Its wealth of data and analy­sis pro­vides very valu­able strate­gic and busi­ness devel­op­ment guid­ance to orga­ni­za­tions at the fron­tier of health and well­ness,” says Alexan­dra More­house, VP of Brand Man­age­ment at Kaiser Per­ma­nente. [Read more…] about Brain Train­ing and Cog­ni­tive Assess­ment Mar­ket Sur­passed $1.3 Bil­lion In 2013

CEO of Cambridge Cognition to speak at 2013 SharpBrains Summit

by

ruth-keir

Ruth Frances Keir runs Cam­bridge Cog­ni­tion (AIM: COG), one of the 10 Com­pa­nies to Watch in 2013/ 2014 accord­ing to our lat­est mar­ket report, which devel­ops and com­mer­cial­izes com­put­erised neu­ropsy­cho­log­i­cal tests used in a vari­ety of health­care and research set­tings. She joined the Cam­bridge Cog­ni­tion board ini­tial­ly in 2010 as a non-exec­u­tive direc­tor, bring­ing to it more than 26 years’ expe­ri­ence in research and busi­ness devel­op­ment posi­tions in the phar­ma­ceu­ti­cal indus­try, as well as a peri­od as Direc­tor of her own con­sul­tan­cy busi­ness, Archea Ltd.

–> To Learn More and Reg­is­ter, click on 2013 Sharp­Brains Vir­tual Sum­mit: Sep­tem­ber 19–20th, 2013